Executive Orders Target Drug Affordability as Manufacturers Prepare for Pricing Model Adjustments

Recent executive orders are set to bring significant changes to the drug pricing and market access landscape, prompting manufacturers to reassess their strategies. Industry expert Alice Valder Curran has detailed steps that pharmaceutical companies should consider in preparation for these developments, emphasizing the importance of proactive measures in response to evolving regulatory actions.

The executive orders aim to address concerns surrounding drug affordability and accessibility, introducing new policies that could reshape pricing structures and market dynamics. Curran highlights key areas where manufacturers may need to focus their efforts, including compliance with updated regulations, adjustments to pricing models, and strategies for maintaining market competitiveness. These recommendations come as stakeholders across the pharmaceutical sector anticipate shifts in both domestic and international markets due to the forthcoming policy changes.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: May 30, 2025

Related posts:

Generic Drug M&A Heats Up as Market Eyes $1.4 Trillion by 2027 Anil Suri Represents Sahajanand Medical Technologies at Pharma & Med Devices Supply Chain Conclave 2025 in Mumbai Pharmacist-Led DPYD Genotype-Guided Dosing Reduces Fluoropyrimidine Toxicity Risks in Cancer Treatment Servier India Launches CDSCO-Approved Ivosidenib for IDH1-Mutated AML and Cholangiocarcinoma

Author

Mark Chiang